The role of nitric oxide in mediating tumour blood flow

Expert Opinion on Therapeutic Targets

Volumn 10, Issue 5, 2006, Pages 689-701

  Van Buren II, George ^a   Camp, E Ramsay ^a   Yang, Anthony D ^a   Gray, Michael J ^a   Fan, Fan ^a   Somcio, Ray ^a   Ellis, Lee M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Angiogenesis; Blood flow; Nitric oxide; Pericyte

Indexed keywords

CAVEOLIN 1; CISPLATIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DYNAMIN II; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCERYL TRINITRATE; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY DC101; N(G) NITRO DEXTRO ARGININE METHYL ESTER; N(G) NITROARGININE; N(G) NITROARGININE METHYL ESTER; NAVELBINE; NEURONAL NITRIC OXIDE SYNTHASE; NEUROPILIN 1; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PROTEIN KINASE (CALCIUM,CALMODULIN) II; PROTEIN KINASE B; PROTEIN KINASE C; SILDENAFIL; SPHINGOMYELIN PHOSPHODIESTERASE; STAT PROTEIN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 1;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL TONE; BREAST ADENOCARCINOMA; CANCER INHIBITION; CANCER RISK; CARCINOGENESIS; CLINICAL TRIAL; COLON ADENOCARCINOMA; DISEASE COURSE; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ERECTILE DYSFUNCTION; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; PANCREAS CANCER; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW; STOMACH CANCER; THYROID CANCER; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION;

ANIMALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

EID: 33749239628     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.10.5.689     Document Type: Review

References (130)

1. FOLKMAN J: What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. (1990) 82(1):4-6.
2. FOLKMAN J: The role of angiogenesis in tumor growth. Semin. Cancer Biol. (1992) 3(2):65-71.
3. FIDLER IJ, ELLIS LM: Neoplastic angiogenesis-not all blood vessels are created equal. N. Engl. J. Med. (2004) 351(3):215-216.
4. FIDLER IJ: The organ microenvironment and cancer metastasis. Differentiation (2002) 70(9-10):498-505.
5. ELLIS LM: Angiogenesis and its role in colorectal tumor and metastasis formation. Semin. Oncol. (2004) 31(6):3-9.
6. CONWAY EM, COLLEN D, CARMELIET P: Molecular mechanisms of blood vessel growth. Cardiovasc. Res. (2001) 49(3):507-521.
7. CARMELIET P, JAIN RK: Angiogenesis in cancer and other diseases. Nature (2000) 407(6801):249-257.
8. BRUNS CJ, LIU W, DAVIS DW et al.: Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer (2000) 89(3):488-499.
9. FIDLER IJ, ELLIS LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell (1994) 79(2):185-188.
10. FIDLER IJ, KUMAR R, BIELENBERG DR, ELLIS LM: Molecular determinants of angiogenesis in cancer metastasis. Cancer J. Sci. Am. (1998) 4:S58-S66.
11. TAKAHASHI Y, BUCANA CD, CLEARY KR, ELLIS LM: p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int. J. Cancer (1998) 79(1):34-38.
12. ELLIS LM, FIDLER IJ: Angiogenesis and metastasis. Eur. J. Cancer (1996) 32A(14):2451-2460.
13. ISHIKAWA T, YOSHIDA N, HIGASHIHARA H et al.: Different effects of constitutive nitric oxide synchase and heme oxygenase on pulmonary or liver metastasis of colon cancer in mice. Clin. Exp. Metastasis (2003) 20(5):445-450.
14. LI CQ, WOGAN GN: Nitric oxide as a modulator of apoptosis. Cancer Lett. (2005) 226(1):1-15.
15. BRUNE B, VON KNETHEN A, SANDAU KB: Nitric oxide (NO): an effector of apoptosis. Cell Death Differ. (1999) 6(10):969-975.
16. LIU L, STAMLER JS: NO: an inhibitor of cell death. Cell Death Differ. (1999) 6(10):937-942.
17. MUNGRUE IN, BREDT DS: nNOS at a glance: implications for brain and brawn. J. Cell Sci. (2004) 117(Pt 13):2627-2629.
18. KIMURA H, ESUMI H: Reciprocal regulation between nitric oxide and vascular endothelial growth factor in angiogenesis. Acta Biochim. Pol. (2003) 50(1):49-59.
19. WILLIAMS EL, DJAMGOZ MB: Nitric oxide and metastatic cell behaviour. Bioessays (2005) 27(12):1228-1238.
20. WANG L, SHI GG, YAO JC et al.: Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer. Gastric Cancer (2005) 8(1):18-28.
21. TOPP SG, ZHANG F, CHATTERJEE T, LINEAWEAVER WC: Role of nitric oxide in surgical flap survival. J. Am. Coll. Surg. (2005) 201(4):628-639.
22. BOO YC, JO H: Flow-dependent regulation of endothelial nitric oxide synthase: role of protein kinases. Am. J. Physiol. Cell Physiol. (2003) 285(3):C499-C508.
23. HAUSFL P, LATADO H, COURJAULT-GAUTIER F, FELLEY-BOSCO E: Src-mediated phosphorylation regulates subcellular distribution and activity of human inducible nitric oxide synthase. Oncogene (2005) 25(2):198-206.
24. JADESKI LC, LALA PK: Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am. J. Pathol. (1999) 155(4):1381-1390.
25. STOJANOVIC A, MARJANOVIC JA, BROVKOVYCH VM et al.: A phosphoinositide 3-kinase-AKT-nitric oxide-cGMP signaling pathway in stimulating platelet secretion and aggregation. J. Biol. Chem. (2006) 281(24):16333-16339.
26. GANSTER RW, TAYLOR BS, SHAO L, GELLER DA: Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-kappa B. Proc. Natl. Acad. Sci. USA (2001) 98(15):8638-8643.
27. DEININGER MH, WYBRANIETZ WA, GRAEPLER FT et al.: Endothelial endostatin release is induced by general cell stress and modulated by the nitric oxide/cGMP pathway. FASEB J. (2003) 17(10):1267-1276.
28. URBICH C, REISSNER A, CHAVAKIS E et al.: Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB J. (2002) 16(7):706-708.
29. LI C, HARRIS MB, VENEMA VJ, VENEMA RC: Endostatin induces acute endothelial nitric oxide and prostacyclin release. Biochem. Biophys. Res. Commun. (2005) 329(3):873-878.
30. 2*-production in the intact coronary endothelium. Am. J. Physiol. Heart Circ. Physiol. (2005) 288(2):H686-H694.
31. ROSIANSKY M, KLIPPER E, SPANEL-BOROWSKI K, MEIDAN R: Inverse relationship between nitric oxide synthases and endothelin-1 synthesis in bovine corpus luteum: interactions at the level of luteal endothelial cell. Endocrinology (2006) (Epub ahead of print).
32. SAHA RN, PAHAN K: Signals for the induction of nitric oxide synthase in astrocytes. Neurochem. Int. (2006) 49(2):154-163.
33. KARPUZOGLU E, AHMED SA: Estrogen regulation of nitric oxide and inducible nitric oxide synthase (iNOS) in immune cells: implications for immunity, autoimmune diseases, and apoptosis. Nitric Oxide (2006) (Epub ahead of print).
34. MONCADA S, HIGGS A: The L-arginine-nitric oxide pathway. N. Engl. J. Med. (1993) 329(27):2002-2012.
35. ISHIKAWA T, MORRIS PL: Interleukin-1{beta} signals through a cJun-N-terminal kinase (JNK)-dependent inducible nitric oxide synthase and nitric oxide production pathway in sertoli epithelial cells. Endocrinology (2006) (Epub ahead of print).
36. PAWATE S, BHAT NR: C-Jun N-terminal kinase (JNK) regulation of iNOS expression in glial cells: predominant role of JNK1 isoform. Antioxid. Redox Signal. (2006) 8(5-6):903-909.
37. RAO CV: Nitric oxide signaling in colon cancer chemoprevention. Mutat. Res. (2004) 555(1-2):107-119.
38. TAYLOR BS, ALARCON LH, BILLIAR TR: Inducible nitric oxide synthase in the liver: regulation and function. Biochemistry (Mosc) (1998) 63(7):766-781.
39. COLASANTI M, PERSICHINI T, MENEGAZZI M et al.: Induction of nitric oxide synthase mRNA expression. Suppression by exogenous nitric oxide. J. Biol. Chem. (1995) 270(45):26731-26733.
40. FULTON D, GRATTON JP, SESSA WC: Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J. Pharmacol. Exp. Ther. (2001) 299(3):818-824.
41. BOO YC, SORESCU GP, BAUER PM et al.: Endothelial NO synthase phosphorylated at SER635 produces NO without requiring intracellular calcium increase. Free Radic. Biol. Med. (2003) 35(7):729-741.
42. BULOTTA S, BARSACCHI R, ROTIROTI D, BORGESE N, CLEMENTI E: Activation of the endothelial nitric-oxide synthase by tumor necrosis factor-alpha. A novel feedback mechanism regulating cell death. J. Biol. Chem. (2001) 276(9):6529-6536.
43. BARSACCHI R, PERROTTA C, BULOTTA S et al.: Activation of endothelial nitric-oxide synthase by tumor necrosis factor-alpha: a novel pathway involving sequential activation of neutral sphingomyelinase, phosphatidylinositol-3′ kinase, and Akt. Mol. Pharmacol. (2003) 63(4):886-895.
44. DE PALMA C, MEACCI E, PERROTTA C, BRUNI P, CLEMENTI E: Endothelial nitric oxide synthase activation by tumor necrosis factor alpha through neutral sphingomyelinase 2, sphingosine kinase 1, and sphingosine 1 phosphate receptors: a novel pathway relevant to the pathophysiology of endothelium. Arterioscler. Thromb. Vasc. Biol. (2006) 26(1):99-105.
45. GALLEY HF, WEBSTER NR: Physiology of the endothelium. Br. J. Anaesth. (2004) 93(1):105-113.
46. SCHLEICHER M, BRUNDIN F, GROSS S, MULLER-ESTERL W, OESS S: Cell cycle-regulated inactivation of endothelial NO synthase through NOSIP-dependent targeting to the cytoskeleton. Mol. Cell. Biol. (2005) 25(18):8251-8258.
47. STAMLER JS, MEISSNER G: Physiology of nitric oxide in skeletal muscle. Physiol. Rev. (2001) 81(1):209-237.
48. SHAH V, LYFORD G, GORES G, FARRUGIA G: Nitric oxide in gastrointestinal health and disease. Gastroenterology (2004) 126(3):903-913.
49. ZICHE M, MORBIDELLI L, MASINI E et al.: Nitric oxide promotes DNA synthesis and cyclic GMP formation in endothelial cells from postcapillary venules. Biochem. Biophys. Res. Commun. (1993) 192(3):1198-1203.
50. CIANCHI F, CORTESINI C, FANTAPPIÁE O et al.: Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis. Am. J. Pathol. (2003) 162(3):793-801.
51. SAND A, ANDERSSON E, FRIED G: Nitric oxide donors mediate vasodilation in human placental arteries partly through a direct effect on potassium channels. Placenta (2006) 27(2-3):181-190.
52. RAGHAVAN SA, DIKSHIT M: Vascular regulation by the L-arginine metabolites, nitric oxide and agmatine. Pharmacol. Res. (2004) 49(5):397-414.
53. GUTTERMAN DD, MIURA H, LIU Y: Redox modulation of vascular tone: focus of potassium channel mechanisms of dilation. Arterioscler. Thromb. Vasc. Biol. (2005) 25(4):671-678.
54. FUKUMURA D, JAIN RK: Role of nitric oxide in angiogenesis and microcirculation in tumors. Cancer Metastasis Rev. (1998) 17(1):77-89.
55. GRIFFITHS MJ, EVANS TW: Inhaled nitric oxide therapy in adults. N. Engl. J. Med. (2005) 353(25):2683-2695.
56. MAURICIO MD, SEGARRA G, MEDINA P et al.: Relaxation and cyclic GMP levels in response to sildenafil in human pulmonary arteries from donors. Eur. J. Pharmacol. (2006) 530(3):259-262.
57. CARSON CC: Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int. (2006) 97(Suppl. 2):39-43; discussion 44-35.
58. BRONTE V, ZANOVELLO P: Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. (2005) 5(8):641-654.
59. MASON MG, NICHOLLS P, WILSON MT, COOPER CE: Nitric oxide inhibition of respiration involves both competitive (heme) and noncompetitive (copper) binding to cytochrome c oxidase. Proc. Natl. Acad. Sci. USA (2006) 103(3):708-713.
60. CLEMENTI E, NISOLI E: Nitric oxide and mitochondrial biogenesis: a key to long-term regulation of cellular metabolism. Comp. Biochem. Physiol. A. Mol. Integr. Physiol. (2005) 142(2):102-110.
61. CHOI BM, PAE HO, JANG SI, KIM YM, CHUNG HT: Nitric oxide as a pro-apoptotic as well as anti-apoptotic modulator. J. Biochem. Mol. Biol. (2002) 35(1):116-126.
62. PALACIOS-CALLENDER M, QUINTERO M, HOLLIS VS, SPRINGETT RJ, MONCADA S: Endogenous NO regulates superoxide production at low oxygen concentrations by modifying the redox state of cytochrome c oxidase. Proc. Natl. Acad. Sci. USA (2004) 101(20):7630-7635.
63. CLEMENTI E, BROWN GC, FOXWELL N, MONCADA S: On the mechanism by which vascular endothelial cells regulate their oxygen consumption. Proc. Natl. Acad. Sci. USA (1999) 96(4):1559-1562.
64. MATEO J, GARCIA-LECEA M, CADENAS S, HERNANDEZ C, MONCADA S: Regulation of hypoxia-inducible factor-1alpha by nitric oxide through mitochondria-dependent and -independent pathways. Biochem. J. (2003) 376(Pt 2):537-544.
65. ARMULIK A, ABRAMSSON A, BETSHOLTZ C: Endothelial/pericyte interactions. Circ. Res. (2005) 97(6):512-523.
66. MCILROY M, O'ROURKE M, MCKEOWN SR, HIRST DG, ROBSON T: Pericytes influence endothelial cell growth characteristics: role of plasminogen activator inhibitor type 1 (PAI-1). Cardiovasc. Res. (2006) 69(1):207-217.
67. BALUK P, HASHIZUME H, MCDONALD DM: Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. (2005) 15(1):102-111.
68. DVORAK HF: Angiogenesis: update 2005. J. Thromb. Haemost. (2005) 3(8):1835-1842.
69. FERRARA N, HILLAN KJ, NOVOTNY W: Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. (2005) 333(2):328-335.
70. WANG Y, FEI D, VANDERLAAN M, SONG A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis (2004) 7(4):335-345.
71. STOELTZING O, LIU W, REINMUTH N et al.: Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis. Ann. Surg. Oncol. (2003) 10(7):722-733.
72. HICKLIN DJ, ELLIS LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. (2005) 23(5):1011-1027.
73. WITMER AN, VAN BLIJSWIJK BC, DAI J et al.: VEGFR-3 in adult angiogenesis. J. Pathol. (2001) 195(4):490-497.
74. FAN F, WEY JS, MCCARTY MF et al.: Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene (2005) 24(16):2647-2653.
75. WEY JS, FAN F, GRAY MJ et al.: Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer (2005) 104(2):427-438.
76. AMBS S, MERRIAM WG, BENNETT WP et al.: Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res. (1998) 58(2):334-341.
77. NAKAMURA Y, YASUOKA H, ZUO H et al.: Nitric oxide in papillary thyroid carcinoma: induction of vascular endothelial growth factor d and correlation with lymph node metastasis. J. Clin. Endocrinol. Metab. (2006) 91(4):1582-1585.
78. NAKAMURA Y, YASUOKA H, TSUJIMOTO M et al.: Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin. Cancer Res. (2006) 12(4):1201-1207.
79. SAKAMOTO H, NAKAMURA T, AKUZAWA N et al.: Reciprocal expression of vascular endothelial growth factor and nitric oxide synthase by coronary arterial wall cells during chronic inhibition of nitric oxide synthesis in rats. Nephron (2002) 92(2):472-474.
80. WANG B, XIONG Q, SHI Q et al.: Genetic disruption of host nitric oxide synthase II gene impairs melanoma-induced angiogenesis and suppresses pleural effusion. Int. J. Cancer (2001) 91(5):607-611.
81. OSTENDORF T, VAN ROEYEN C, WESTENFELD R et al.: Inducible nitric oxide synthase-derived nitric oxide promotes glomerular angiogenesis via upregulation of vascular endothelial growth factor receptors. J. Am. Soc. Nephrol. (2004) 15(9):2307-2319.
82. MILKIEWICZ M, HUDLICKA O, BROWN MD, SILGRAM H: Nitric oxide, VEGF, and VEGFR-2: interactions in activity-induced angiogenesis in rat skeletal muscle. Am. J. Physiol. Heart Circ. Physiol. (2005) 289(1):H336-H343.
83. QUINTERO M, BRENNAN PA, THOMAS GJ, MONCADA S: Nitric oxide is a factor in the stabilization of hypoxia-inducibte factor-1alpha in cancer: role of free radical formation. Cancer Res. (2006) 66(2):770-774.
84. CAI J, JIANG WG, AHMED A, BOULTON M: Vascular endothelial growth factor-induced endothelial cell proliferation is regulated by interaction between VEGFR-2, SH-PTP1 and eNOS. Microvasc. Res. (2006) 71(1):20-31.
85. HOOD JD, MEININGER CJ, ZICHE M, GRANGER HJ: VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am. J. Physiol. (1998) 274(3):H1054-H1058.
86. ZICHE M, MORBIDELLI L, CHOUDHURI R et al.: Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J. Clin. Invest. (1997) 99(11):2625-2634.
87. PARENTI A, MORBIDELLI L, CUI XL et al.: Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J. Biol. Chem. (1998) 273(7):4220-4226.
88. KROLL J, WALTENBERGER J: VEGF-A induces expression of eNOS and NOS in endothelial cells via VEGF receptor-2 (KDR). Biochem. Biophys. Res. Commun. (1998) 252(3):743-746.
89. WILLIAMS JL, CARTLAND D, HUSSAIN A, EGGINTON S: A differential role for nitric oxide in two forms of physiological angiogenesis in mouse. J. Physiol. (2005) 570(3):445-454.
90. FUKUMURA D, GOHONGI T, KADAMBI A et al.: Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc. Natl. Acad. Sci. USA (2001) 98(5):2604-2609.
91. AICHER A, HEESCHEN C, MILDNER-RIHM C et al.: Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. (2003) 9(11):1370-1376.
92. HELLMUTH M, PAULUKAT J, NINIC R, PFEILSCHIFTER J, MÈUHL H: Nitric oxide differentially regulates pro- and anti-angiogenic markers in DLD-1 colon carcinoma cells. FEBS Lett. (2004) 563(1-3):98-102.
93. GALLO O, MASINI E, MORBIDELLI L et al.: Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J. Natl. Cancer Inst. (1998) 90(8):587-596.
94. ABDOLLAHI A, HAHNFELDT P, MAERCKER C et al.: Endostatin's antiangiogenic signaling network. Mol. Cell (2004) 13(5):649-663.
95. JONES MK, TSUGAWA K, TARNAWSKI AS, BAATAR D: Dual actions of nitric oxide on angiogenesis: possible roles of PKC, ERK, and AP-1. Biochem. Biophys. Res. Commun. (2004) 318(2):520-528.
96. ZICHE M, MORBIDELLI L, MASINI E et al.: Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J. Clin. Invest. (1994) 94(5):2036-2044.
97. KASHIWAGI S, IZUMI Y, GOHONGI T et al.: NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J. Clin. Invest. (2005) 115(7):1816-1827.
98. COOKE JP: Flow, NO, and atherogenesis. Proc. Natl. Acad. Sci. USA (2003) 100(3):768-770.
99. STANKEVICIUS E, KEVELAITIS E, VAINORIUS E, SIMONSEN U: [Role of nitric oxide and other endothelium-derived factors]. Medicina (Kaunas) (2003) 39(4):333-341.
100. MONCADA S, HIGGS EA: The discovery of nitric oxide and its role in vascular biology. Br. J. Pharmacol. (2006) 147(Suppl. 1):S193-S201.
101. REES DD, PALMER RM, SCHULZ R, HODSON HF, MONCADA S: Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol. (1990) 101(3):746-752.
102. LAHERA V, SALOM MG, MIRANDA-GUARDIOLA F, MONCADA S, ROMERO JC: Effects of NG-nitro-L-arginine methyl ester on renal function and blood pressure. Am. J. Physiol. (1991) 261(6 Pt 2):F1033-F1037.
103. HAMPL V, HUANG JM, WEIR EK, ARCHER SL: Activation of the cGMP-dependent protein kinase mimics the stimulatory effect of nitric oxide and cGMP on calcium-gated potassium channels. Physiol. Res. (1995) 44(1):39-44.
104. BOLOTINA VM, NAJIBI S, PALACINO JJ, PAGANO PJ, COHEN RA: Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature (1994) 368(6474):850-853.
105. RAIJ L: Workshop: hypertension and cardiovascular risk factors: role of the angiotensin II-nitric oxide interaction. Hypertension (2001) 37(2 Part 2):767-773.
106. FARROW B, SUGIYAMA Y, CHEN A et al.: Inflammatory mechanisms contributing to pancreatic cancer development. Ann. Surg. (2004) 239(6):763-769; discussion 769-771.
107. MAEDA H, FANG J, INUTSUKA T, KITAMOTO Y: Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int. Immunopharmacol. (2003) 3(3):319-328.
108. DING X, HIRAKU Y, MA N et al.: Inducible nitric oxide synthase-dependent DNA damage in mouse model of inflammatory bowel disease. Cancer Sci. (2005) 96(3):157-163.
109. FURTMULLER PG, JANTSCHKO W, ZEDERBAUER M et al.: Peroxynitrite efficiently mediates the interconversion of redox intermediates of myeloperoxidase. Biochem. Biophys. Res. Commun. (2005) 337(3):944-954.
110. YAMAGUCHI K, SAITO H, ORO S et al.: Expression of inducible nitric oxide synthase is significantly correlated with expression of vascular endothelial growth factor and dendritic cell infiltration in patients with advanced gastric carcinoma. Oncology (2005) 68(4-6):471-478.
111. KOJIMA M, MORISAKI T, TSUKAHARA Y et al.: Nitric oxide synthase expression and nitric oxide production in human colon carcinoma tissue. J. Surg. Oncol. (1999) 70(4):222-229.
112. NIU XJ, WANG ZR, WU SL et al.: Relationship between inducible nitric oxide synthase expression and angiogenesis in primary gallbladder carcinoma tissue. World J. Gastroenterol. (2004) 10(5):725-728.
113. LOIBL S, BUCK A, STRANK C et al.: The role of early expression of inducible nitric oxide synthase in human breast cancer. Eur. J. Cancer (2005) 41(2):265-271.
114. YANG AD, BAUER TW, CAMP ER et al.: Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy. Cancer (2005) 103(8):1561-1570.
115. DI TOMASO E, CAPEN D, HASKELL A et al.: Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers. Cancer Res. (2005) 65(13):5740-5749.
116. ICHINOE M, MIKAMI T, SHIRAISHI H, OKAYASU I: High microvascular density is correlated with high VEGF, iNOS and COX-2 expression in penetrating growth-type early gastric carcinomas. Histopathology (2004) 45(6):612-618.
117. KASPER HU, WOLF H, DREBBER U, WOLF HK, KERN MA: Expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic adenocarcinoma: correlation with microvessel density. World J. Gastroenterol. (2004) 10(13):1918-1922.
118. CAMP ER, YANG A, LIU W et al.: Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer. Clin. Cancer Res. (2006) 12(8):2628-2633.
119. JENKINS DC, CHARLES IG, THOMSEN LL et al.: Roles of nitric oxide in tumor growth. Proc. Natl. Acad. Sci. USA (1995) 92(10):4392-4396.
120. FUKUMURA D, YUAN F, ENDO M, JAIN RK: Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. Am. J. Pathol. (1997) 150(2):713-725.
121. WANG Z, COOK T, ALBER S et al.: Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vascularity. Cancer Res. (2004) 64(4):1386-1395.
122. CHEN HH, SU WC, CHOU CY et al.: Increased expression of nitric oxide synthase and cyclooxygenase-2 is associated with poor survival in cervical cancer treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. (2005) 63(4):1093-1100.
123. RIGANTI C, MIRAGLIA E, VIARISIO D et al.: Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res. (2005) 65(2):516-525.
124. YASUDA H, YAMAYA M, NAKAYAMA K et al.: Randomized Phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin. Oncol. (2006) 24(4):688-694.
125. MUERKOSTER SS, LUST J, ARLT A et al.: Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1beta and NO lead to inactivation of caspases. Oncogene (2006) 25(28):3973-3981.
126. MOCELLIN S, PROVENZANO M, ROSSI CR et al.: Induction of endothelial nitric oxide synthase expression by melanoma sensitizes endothelial cells to tumor necrosis factor-driven cytotoxicity. Clin. Cancer Res. (2004) 10(20):6879-6886.
127. BOGDAN C: Nitric oxide and the immune response. Nat. Immunol. (2001) 2(10):907-916.
128. BINGISSER RM, HOLT PG: Immunomodulating mechanisms in the lower respiratory tract: nitric oxide mediated interactions between alveolar macrophages, epithelial cells, and T-cells. Swiss Med. Wkly. (2001) 131(13-14):171-179.
129. PAOLUCCI C, ROVERE P, DE NADAI C, MANFREDI AA, CLEMENTI E: Nitric oxide inhibits the tumor necrosis factor alpha-regulated endocyrosis of human dendritic cells in a cyclic GMP-dependent way. J. Biol. Chem. (2000) 275(26):19638-19644.
130. PAOLUCCI C, BURASTERO SE, ROVERE-QUERINI P et al.: Synergism of nitric oxide and maturation signals on human dendritic cells occurs through a cyclic GMP-dependent pathway. J. Leukoc. Biol. (2003) 73(2):253-262.